Literature DB >> 9733869

Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.

J M Lubinski1, L Wang, A M Soulika, R Burger, R A Wetsel, H Colten, G H Cohen, R J Eisenberg, J D Lambris, H M Friedman.   

Abstract

Many microorganisms encode proteins that interact with molecules involved in host immunity; however, few of these molecules have been proven to promote immune evasion in vivo. Herpes simplex virus type 1 (HSV-1) glycoprotein C (gC) binds complement component C3 and inhibits complement-mediated virus neutralization and lysis of infected cells in vitro. To investigate the importance of the interaction between gC and C3 in vivo, we studied the virulence of a gC-null strain in complement-intact and C3-deficient animals. Using a vaginal infection model in complement-intact guinea pigs, we showed that gC-null virus grows to lower titers and produces less severe vaginitis than wild-type or gC rescued virus, indicating a role for gC in virulence. To determine the importance of complement, studies were performed with C3-deficient guinea pigs; the results demonstrated significant increases in vaginal titers of gC-null virus, while wild-type and gC rescued viruses showed nonsignificant changes in titers. Similar findings were observed for mice where gC null virus produced significantly less disease than gC rescued virus at the skin inoculation site. Proof that C3 is important was provided by studies of C3 knockout mice, where disease scores of gC-null virus were significantly higher than in complement-intact mice. The results indicate that gC-null virus is approximately 100-fold (2 log10) less virulent that wild-type virus in animals and that gC-C3 interactions are involved in pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733869      PMCID: PMC110183          DOI: 10.1128/JVI.72.10.8257-8263.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

2.  Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

3.  Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice.

Authors:  R D Dix; R R McKendall; J R Baringer
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

4.  Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates.

Authors:  H M Friedman; J C Glorioso; G H Cohen; J C Hastings; S L Harris; R J Eisenberg
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.

Authors:  L F Fries; H M Friedman; G H Cohen; R J Eisenberg; C H Hammer; M M Frank
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

6.  In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  T Nagashunmugam; J Lubinski; L Wang; L T Goldstein; B S Weeks; P Sundaresan; E H Kang; G Dubin; H M Friedman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells.

Authors:  H M Friedman; G H Cohen; R J Eisenberg; C A Seidel; D B Cines
Journal:  Nature       Date:  1984 Jun 14-20       Impact factor: 49.962

8.  An inherited deficiency of the third component of complement, C3, in guinea pigs.

Authors:  R Burger; J Gordon; G Stevenson; G Ramadori; B Zanker; U Hadding; D Bitter-Suermann
Journal:  Eur J Immunol       Date:  1986-01       Impact factor: 5.532

9.  Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.

Authors:  T A McNearney; C Odell; V M Holers; P G Spear; J P Atkinson
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA.

Authors:  Y M Centifanto-Fitzgerald; T Yamaguchi; H E Kaufman; M Tognon; B Roizman
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

View more
  41 in total

1.  Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease.

Authors:  C E Saldanha; J Lubinski; C Martin; T Nagashunmugam; L Wang; H van Der Keyl; R Tal-Singer; H M Friedman
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 3.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  ICP22 is required for wild-type composition and infectivity of herpes simplex virus type 1 virions.

Authors:  Joseph S Orlando; John W Balliet; Anna S Kushnir; Todd L Astor; Magdalena Kosz-Vnenchak; Stephen A Rice; David M Knipe; Priscilla A Schaffer
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 6.  Immune responses to herpesviral vectors.

Authors:  Deborah A Ryan; Howard J Federoff
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

7.  Structural rearrangement within an enveloped virus upon binding to the host cell.

Authors:  David G Meckes; John W Wills
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

8.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

9.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

10.  Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Authors:  Natasha M Girgis; Brian C Dehaven; Xin Fan; Kendra M Viner; Mohammad Shamim; Stuart N Isaacs
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.